As 2024 draws to a close, Archbow Consulting reflects on a year of dynamic change within the pharmaceutical industry.
Navigating the Evolving Pharma Landscape: A Year in Review
read more
BLOG
Revolutionizing Patient Care: The Top 5 Benefits of Investing in Innovation
Why manufacturers must embrace innovative trends to stay ahead
Are Direct-to-Patient Access Models the Future of Pharma?
Understanding the opportunity to sell directly to patients via a cash model
Key Takeaways from NASP 2024
The 2024 National Association of Specialty Pharmacy (NASP) conference showcased a landscape of rapid innovation and evolving industry trends.
Digital Solutions in Patient Services
An Interview on Best Practices and Trends in 2025
Managing Your Network: Are Your Specialty Pharmacies Meeting Program Expectations?
Discover four essential strategies manufacturers need to transform their Specialty Pharmacy networks into efficient powerhouses to enhance patient care, foster innovative HCP relationships, build robust payer partnerships, and ensure product accessibility.
Designing a Pharma Hub for Combination Products
Designing a pharmaceutical hub for combination or companion products is a complex undertaking that requires careful planning and design execution.
Differentiate Your Specialty Pharmacy: A Blueprint for a Valuable Partnership with Pharma Manufacturers
Pharmaceutical manufacturers have many partner choices in today’s competitive Specialty Pharmacy (SP) space. By focusing on the following key areas, SPs can elevate their value proposition and drive mutual success.
How To Maximize Biotech Vendor Marketing
Biotech marketing requires a unique blend of scientific expertise, strategic planning, and creative execution.
Logistics Reimagined: The Benefits of Using a Virtual 3PL Vendor
As the world becomes increasingly digitized, a novel idea of a virtual third-party logistics (3PL) vendor has been established in the pharmaceutical industry.
Keep Your Planning in the Driver’s Seat: Review Your 2025 Patient Services Strategy Now
Navigate the open road ahead with confidence. Start planning today and ensure your 2025 program delivers the support your patients need.
Health System Specialty Pharmacies are on the Rise: What Manufacturers Need to Know
Health System Specialty Pharmacies are on the Rise: What Manufacturers Need to Know
Pre-Asembia Checklist for Market Access Teams
Pre-Asembia Checklist for Market Access Teams
A First-Hand Account of 3PLs – A Podcast on Distribution Best Practices
A First-Hand Account of 3PLs – A Podcast on Distribution Best Practices
Is a Direct-to-Patient Access Model Viable For My Product?
Is a Direct-to-Patient Access Model Viable For My Product?
Hub Implementation: The Key to Product Launches
Hub Implementation: The Key to Product Launches
Revving Up for 2024: Market Access Kick-Start Resources
Revving Up for 2024: Market Access Kick-Start Resources
Key Market Access Trends to Watch in 2024
Key Market Access Trends to Watch in 2024
Don’t Let Your Pharma Program Fall Behind – Optimize It Now
Don’t Let Your Pharma Program Fall Behind – Optimize It Now
The Key to Pharmaceutical Commercial Success
The Key to Pharmaceutical Commercial Success
Outlook on Oncology: Key Takeaways from the AVBCC 2023 Educational Summit
Outlook on Oncology: Key Takeaways from the AVBCC 2023 Educational Summit
Webinar Archive: Pharmaceutical HUBs are Underutilized; Yours Doesn’t Have to Be
HUBs are Underutilized; Yours Doesn’t Have to Be
Key Takeaways from the Health Systems & Pharma Partnering Summit 2023
Key Takeaways from the Health Systems & Pharma Partnering Summit 2023
Five Takeaways from Medicare’s 10 Drugs Up for Price Negotiation
Five Takeaways from Medicare’s 10 Drugs Up for Price Negotiation
Pharma Has a Pull-Through Problem; The Answer is Data
Pharma Has a Pull-Through Problem; The Answer is Data
The Perils of Pull-Through
The Perils of Pull-Through
6 Essential Strategies for Successful Clinical Adherence
6 Essential Strategies for Successful Clinical Adherence
Using Targeted Market Research to Improve Future Adoption of Cell and Gene Therapies
Using Targeted Market Research to Improve Future Adoption of Cell and Gene Therapies
How Pharma Can Turn Data into Insights: Effectively Leveraging Pharma and Market Access Data
How Pharma Can Turn Data into Insights: Effectively Leveraging Pharma and Market Access Data
Take the Pain out of Conversations About Coverage
Take the Pain out of Conversations About Coverage
Market Access POV: ICER and Specialty Drug Coverage
Market Access POV: ICER and Specialty Drug Coverage
Key Takeaways from the 2023 Asembia Specialty Pharmacy Summit
Key Takeaways from the 2023 Asembia Specialty Pharmacy Summit
How Manufacturers Can Optimize Hub Services
How Manufacturers Can Optimize Hub Services
Conversation Starters to Drive Impactful Discussions with Specialty Pharmacies
Conversation Starters to Drive Impactful Discussions with Specialty Pharmacies
Best Practices for Vendor Selection and Management
Best Practices for Vendor Selection and Management
3 Market Access Takeaways from SXSW 2023
What market access teams should be thinking about after 2023’s SXSW Conference
10 Market Access Trends to Watch for in 2023
Our experts teamed up with Pharmaceutical Executive to identify 10 Market Access Trends to Watch for in 2023, spanning patients, prescribers
Well-designed Access and Affordability Programs can be a Key Differentiator for Pharma Companies
Manufacturers recognize access and affordability programs as key differentiators that build brand loyalty with elevated customer experiences
Effectively Navigate the Rapidly Evolving Pharmacy Market
Manufacturers recognize access and affordability programs as key differentiators that build brand loyalty with elevated customer experiences
How Effective Product Distribution Strategies Maximize the Pharmaceutical Supply Chain
How pharmaceutical manufacturers can efficiently and effectively get product into the hands of patients
Webinar Archive: 11 Market Access Questions to Address Prior to Launching Your First Specialty Drug
Webinar Archive: Get answers to the eleven key questions that will help guide commercial teams in effectively launching specialty products.
Best Practices for Improving Program Performance Through Well-Managed SP Relationships
With a carefully crafted approach, SPs & Manufacturers can enjoy partnerships that drive access, adherence, and overall program performance
Control vs. Access: Why Clinical Characteristics Should Guide Specialty Pharmacy Strategy
When it comes to pharmacy network design, there is a careful balance between access and control.
How Equitable is Your Pharmacy Dispensing Strategy?
Pharmacy dispensing network strategies are an essential linchpin in any product’s commercial success.
10 Steps to Building an Integrated Pharmaceutical Launch Strategy
The key to building an integrated model for new products is understanding which steps in launch planning are essential and when to take them
How Patient Support Programs Can Compliantly Interact with Commercial Teams
With the right approach, patient support programs can mitigate the potential negative impacts of regulatory compliance
Effective and Practical Ways to Impact Health Inequity Now
Practical lists of questions spanning distribution, access, and affordability that market access teams can use to impact health equity today
Want to Build a Market-Leading Pharmaceutical Patient Support Program? Ask a Nurse.
In celebration of Nurses Day, explore how nurses working for pharmaceutical consulting companies benefit manufacturers’ commercial goals
11 Market Access Questions to Address Prior to Launching Your First Specialty Drug
The answers to these eleven questions will help guide commercial teams in effectively launching specialty products.
How Quality in Patient Services Programs Can be a Powerful Differentiator for Pharma and Biotech
Poor quality within a HUB can lead to delays in patient treatment, loss of prescriber confidence, and users seeking alternative avenues.
Maximizing Specialty Pharmacy Contracts
When approached strategically, contracting with SP networks can positively impact patient experience and the company’s bottom line.
What the CMS Final Rule on Copay Programs Means for Pharmaceutical Manufacturers
It is vital for pharmaceutical manufacturers to consider how much financial and reputational risk they may face as a result of the pending C